Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$240.74 USD

240.74
203,030

+0.75 (0.31%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $240.81 +0.07 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics

by Zacks Equity Research

The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.

Zacks Equity Research

Here's Why You Should Hold Varian Medical (VAR) Stock Now

by Zacks Equity Research

Varian (VAR) expects the Cancer Treatment Services International buyout to prove accretive to earnings per share during fiscal 2021.

Zacks Equity Research

Amedisys Rides on New Buyouts, Strength in Personal Care Arm

by Zacks Equity Research

Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.

Zacks Equity Research

Veeva's Vault eTMF Implemented by South Korea's Celltrion

by Zacks Equity Research

Management at Veeva (VEEV) expects Vault subscription revenues to grow a significant 40% in fiscal 2020.

Zacks Equity Research

Walgreens Boots (WBA) Q3 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Walgreens Boots' (WBA) Retail Pharmacy USA division gains traction from comparable prescription volume growth and a sturdy retail prescription market.

Zacks Equity Research

Boston Scientific Strong on Growth Goals and Future Launches

by Zacks Equity Research

This long-range strategy will aid Boston Scientific (BSX) to deliver a solid financial footing across its MedSurg, Rhythm and Neuro plus Cardiovascular segments.

Zacks Equity Research

Varian (VAR) & Tennessee Oncology to Implement Use of Noona

by Zacks Equity Research

Varian's (VAR) core Oncology unit gets a boost from the latest collaboration with Tennessee Oncology.

Zacks Equity Research

Here's Why You Should Add Bruker (BRKR) to Your Portfolio

by Zacks Equity Research

Investor confidence in Bruker stock (BRKR) is high on substantial potential of MALDI Biotyper.

Zacks Equity Research

Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY (XRAY) focuses on innovation through active R&D.

Zacks Equity Research

Veeva's Submissions & RIM Implemented by Sumitomo Dainippon

by Zacks Equity Research

Veeva's (VEEV) flagship Vault platform witnesses robust demand.

Zacks Equity Research

Teleflex (TFX) Shares Down on Respiratory Care Product Recall

by Zacks Equity Research

Teleflex (TFX) issued a statement saying consumers who own the tampered product should immediately discontinue use and return all affected products.

Zacks Equity Research

Bruker (BRKR) Hits a 52-Week High on Solid Growth Drivers

by Zacks Equity Research

Bruker (BRKR) gains from several crucial product launches and acquisitions.

Zacks Equity Research

Hill-Rom (HRC) Gains on Product Launch, Prudent Buyouts

by Zacks Equity Research

The contribution from new products is substantial to bolster top-line growth during the first half of fiscal 2019 at Hill-Rom (HRC).

Zacks Equity Research

Here's Why You Should Hold GNC Holdings (GNC) Stock for Now

by Zacks Equity Research

GNC Holdings (GNC) continues to witness investors' confidence, courtesy of a few positive factors like strategic new partnerships.

Zacks Equity Research

Here's Why You Should Buy Masimo (MASI) Stock Right Now

by Zacks Equity Research

Masimo (MASI) receives FDA clearance for its O3 Regional Oximetry for utilization on neonatal and infant patients.

Zacks Equity Research

Bruker (BRKR) Launches the MALDI Biotyper Sirius System

by Zacks Equity Research

The launch is a milestone for Bruker (BRKR) in assay research and clinical studies for fast antibiotic-resistance testing.

Zacks Equity Research

IDEXX (IDXX) Gains Traction From Solid CAG, Global Strength

by Zacks Equity Research

IDEXX (IDXX) consistently benefits from strong organic growth, driven by robust sales at the CAG business, fueled by a firm global Catalyst adoption.

Zacks Equity Research

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Hologic (HOLX) is generating consistent positive results, courtesy of growth initiatives.

Zacks Equity Research

Hologic (HOLX) Inks Deal to Acquire SuperSonic Imagine

by Zacks Equity Research

The acquisition of SuperSonic Imagine is in sync with Hologic's (HOLX) strategy to provide wide-ranging screening, interventional and surgical solutions.

Urmimala Biswas headshot

Near-Term Outlook for Medical Instruments Industry Bleak

by Urmimala Biswas

Complex regulatory hurdles come in the way of any infrastructural or technology growth in the Medical Instruments space.

Zacks Equity Research

Haemonetics on a High Owing to Firm Plasma Arm, Global Growth

by Zacks Equity Research

Continued traction in new business wins and expansion of geographies are lifting Haemonetics' (HAE) performance of late.

Zacks Equity Research

Here's Why You Should Invest in Haemonetics (HAE) Stock Now

by Zacks Equity Research

Haemonetics (HAE) benefits from impressive uptick of Hemostasis Management revenues.

Zacks Equity Research

NuVasive Grows on Strong Product Adoption Amid Pricing Woe

by Zacks Equity Research

Introduction of multiple products within the Spinal Hardware, balanced revenue growth across key operating segments and robust international sales perk up NuVasive's (NUVA) share price.

Zacks Equity Research

Haemonetics' Plant Sell-Off to CLS Plasma to be Strategic Fit

by Zacks Equity Research

This impending divestment remains integral to Haemonetics' (HAE) asset optimization strategy that aims at improving its operational performance and focusing on core competencies.

Zacks Equity Research

Teleflex (TFX) Hits New 52-Week High on Solid Growth Drivers

by Zacks Equity Research

Teleflex (TFX) gains from acquisition of NeoTract and Vascular Solutions.